



International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE TELEMEDICINE IN HYPERTENSION MANAGEMENT: A STRUCTURED REVIEW OF TECHNOLOGICAL INNOVATIONS, SOCIAL BARRIERS, AND IMPACTS ON PATIENT QUALITY OF LIFE

DOI [https://doi.org/10.31435/ijitss.1\(49\).2026.5193](https://doi.org/10.31435/ijitss.1(49).2026.5193)

RECEIVED 26 January 2026

ACCEPTED 19 March 2026

PUBLISHED 30 March 2026

LICENSE



The article is licensed under a **Creative Commons Attribution 4.0 International License**.

© The author(s) 2026.

This article is published as open access under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

TELEMEDICINE IN HYPERTENSION MANAGEMENT: A STRUCTURED REVIEW OF TECHNOLOGICAL INNOVATIONS, SOCIAL BARRIERS, AND IMPACTS ON PATIENT QUALITY OF LIFE

Kamila Teresa Kańska (Corresponding Author, Email: kamakanska@gmail.com)
Pomeranian Medical University, Szczecin, Poland
ORCID ID: 0009-0005-2702-7013

Maciej Tomasz Wiczorek
Pomeranian Medical University, Szczecin, Poland
ORCID ID: 0009-0007-4058-7650

Jeremi Leon Jasiński
Pomeranian Medical University, Szczecin, Poland
ORCID ID: 0009-0004-1690-5936

Karolina Magda Leszczyńska
Pomeranian Medical University, Szczecin, Poland
ORCID ID: 0009-0000-6427-7269

Karolina Krawczyk
Pomeranian Medical University, Szczecin, Poland
ORCID ID: 0009-0005-1191-5788

Karolina Julia Hak
Independent Public Provincial Integrated Hospital in Szczecin, Szczecin, Poland
ORCID ID: 0009-0009-7641-0237

Weronika Napierała
Jerzy Popiełuszko Hospital of Bielany, Warsaw, Poland
ORCID ID: 0009-0005-1411-4046

Alicja Maria Mitan
Fryderyk Chopin University Clinical Hospital in Rzeszów, Rzeszów, Poland
ORCID ID: 0009-0004-5617-5034

Aleksandra Maria Tomaszewska
University Clinical Hospital of Białystok, Białystok, Poland
ORCID ID: 0009-0000-4684-0492

Anna Krzysztofik
Pomeranian Medical University, Szczecin, Poland
ORCID ID: 0009-0002-3130-1917

ABSTRACT

Hypertension remains insufficiently controlled in many adult populations despite established pharmacological therapies, prompting increasing adoption of telemedicine and digital health interventions in chronic disease management (Raquib et al., 2025; Ali et al., 2024).

Objective: This structured review aimed to synthesize current evidence on the clinical effectiveness of telemedicine interventions in hypertension management, categorize technological innovations, identify social and implementation barriers, and evaluate impacts on patient engagement and quality of life.

Methods: This study was conducted as a structured evidence synthesis integrating findings from peer-reviewed publications published between 2020 and 2026, including systematic reviews, meta-analyses, randomized controlled trials, scoping reviews, usability studies, and implementation analyses addressing telemedicine and digital health interventions in adult hypertension management (Li et al., 2020; Yang et al., 2026; Sakima et al., 2025; Khalid et al., 2023). Publications were selected based on their relevance to clinical effectiveness, technological characteristics, implementation barriers, patient engagement, and patient-reported outcomes.

Protocol Registration: This study was not prospectively registered, as it was designed as a structured integrative review rather than a PRISMA-based systematic review involving a de novo database search.

Results: Across multiple meta-analyses and randomized trials, telemedicine interventions were associated with modest but statistically significant reductions in systolic blood pressure, with greater effects observed in hybrid models integrating remote monitoring and structured professional support (Kassavou et al., 2022; Lakshminarayan et al., 2026). However, heterogeneity in intervention design, engagement variability, digital literacy barriers, and reimbursement constraints influenced effectiveness across populations (Khoong et al., 2021; Buis et al., 2024; Shanab et al., 2025). Evidence regarding long-term quality-of-life outcomes remains limited and inconsistently reported (Meda et al., 2024; Raquib et al., 2025).

Conclusions: Telemedicine represents a promising yet context-dependent model for hypertension management. Achieving sustainable and equitable impact requires integration within multidisciplinary care frameworks.

KEYWORDS

Telemedicine, Hypertension, Remote Blood Pressure Monitoring, mHealth, Health Equity, Patient Engagement

CITATION

Kamila Teresa Kańska, Maciej Tomasz Wiczorek, Jeremi Leon Jasiński, Karolina Magda Leszczyńska, Karolina Krawczyk, Karolina Julia Hak, Weronika Napierała, Alicja Maria Mitan, Aleksandra Maria Tomaszewska, Anna Krzysztofik. (2026) Telemedicine in Hypertension Management: A Structured Review of Technological Innovations, Social Barriers, and Impacts on Patient Quality of Life. *International Journal of Innovative Technologies in Social Science*. 1(49). doi: 10.31435/ijitss.1(49).2026.5193

COPYRIGHT

© The author(s) 2026. This article is published as open access under the **Creative Commons Attribution 4.0 International License (CC BY 4.0)**, allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

1. Introduction

Hypertension constitutes a major global health burden and remains a leading risk factor for cardiovascular morbidity and mortality (Raquib et al., 2025). Despite advancements in antihypertensive pharmacotherapy, a substantial proportion of adults fail to achieve optimal blood pressure control, reflecting persistent gaps in detection, treatment adherence, and long-term management (Raquib et al., 2025; Ali et al., 2024). Even in high-resource settings, blood pressure control rates remain suboptimal, with structural and behavioral determinants contributing to ongoing risk (Shanab et al., 2025; Khoong et al., 2021).

Telemedicine and digital health interventions have been increasingly adopted as strategies to enhance hypertension management through remote monitoring, behavioral support, and provider-patient interaction facilitated by information and communication technologies (Ali et al., 2024; Sakima et al., 2025). Digital health interventions encompass a spectrum of modalities, including smartphone applications, text messaging systems, web-based platforms, remote blood pressure monitoring devices, wearable sensors, and integrated teleconsultation services (Sakima et al., 2025; Sinou et al., 2024). These approaches aim to reduce clinical inertia, enhance patient self-management, and improve access to care, particularly in populations facing structural barriers (Shanab et al., 2025; Khalid et al., 2023).


Systematic reviews and meta-analyses suggest that telemedicine and mHealth interventions are associated with statistically significant reductions in systolic and diastolic blood pressure compared with usual

care, although effect sizes vary and heterogeneity is substantial (Li et al., 2020; Yang et al., 2026; Sakima et al., 2025). For example, digital interventions have demonstrated mean reductions in systolic blood pressure across multiple follow-up periods and delivery modes, including smartphone applications, text messaging, and web-based platforms (Sakima et al., 2025). Similarly, mobile health self-management strategies have been associated with improvements in blood pressure control and self-management behaviors, although methodological quality and risk of bias vary across studies (Li et al., 2020).

However, the expansion of telemedicine has also exposed structural inequities in digital access, technological literacy, reimbursement models, and implementation capacity (Khoong et al., 2021; Khalid et al., 2023). Populations experiencing digital barriers—including older adults, individuals with limited educational attainment, racial and ethnic minority groups, and low-income communities—may not derive equivalent benefit from digital interventions without tailored implementation strategies (Khoong et al., 2021; Poblete et al., 2023). Moreover, disparities in hypertension prevalence and control remain particularly pronounced among African women and minoritized populations, underscoring the need for gender-responsive and equity-oriented digital health design (Djibrilla et al., 2026; Shanab et al., 2025).

Beyond clinical endpoints, patient engagement has emerged as a central determinant of telemedicine effectiveness (Rosa et al., 2024; Hu et al., 2026). Communication strategies at interpersonal, team, and system levels influence patient activation, adherence, satisfaction, and sustained platform use (Hu et al., 2026). Engagement mechanisms interact with technological design and implementation context to shape both clinical and psychosocial outcomes (Khalid et al., 2023; Rosa et al., 2024).

Given the rapid evolution of telemedicine technologies and the complexity of implementation contexts, there is a need for a structured synthesis integrating clinical effectiveness, technological innovation, social determinants, and quality-of-life implications within a single analytical framework (Raquib et al., 2025; Shanab et al., 2025).



Conceptual synthesis based on Hu et al. (2026); Khalid et al. (2023); Rosa et al. (2024); Shanab et al. (2025).

Fig. 1. Conceptual Framework Linking Telemedicine Innovation, Implementation Context, Patient Engagement, and Clinical Outcomes

Caption: Conceptual model synthesizing technological innovation (digital health interventions and remote monitoring), multilevel communication strategies, implementation determinants, and their influence on patient engagement and clinical outcomes in hypertension management. Based on synthesis of Hu et al. (2026), Khalid et al. (2023), Shanab et al. (2025), and Rosa et al. (2024).

This review aims to:

- Synthesize evidence on the clinical effectiveness of telemedicine interventions for hypertension management.
- Categorize technological innovations and delivery models.
- Identify social, structural, and implementation barriers influencing outcomes.
- Examine impacts on patient engagement and quality of life.
- Propose an integrated framework for equitable and sustainable telemedicine implementation.

2. Methodology

2.1 Study Design

This study was conducted as a structured review synthesizing evidence from systematic reviews, meta-analyses, randomized controlled trials (RCTs), scoping reviews, usability studies, and implementation science analyses addressing telemedicine interventions in hypertension management (Li et al., 2020; Yang et al., 2026; Sakima et al., 2025; Khalid et al., 2023). The objective was to integrate clinical, technological, social, and engagement-related dimensions within a unified analytical framework.

The predefined corpus of publications was selected to ensure thematic coherence and methodological transparency.

2.2 Eligibility Criteria

Studies were eligible for inclusion if they:

- Examined telemedicine, digital health, mHealth, remote blood pressure monitoring, wearable devices, or teleconsultation in adult hypertension management (Ali et al., 2024; Sakima et al., 2025).
- Reported clinical outcomes related to blood pressure reduction or control (Yang et al., 2026; Lakshminarayan et al., 2026).
- Evaluated behavioral, engagement, adherence, or self-management outcomes (Li et al., 2020; Kassavou et al., 2022; Rosa et al., 2024).
- Addressed implementation determinants, communication strategies, or social disparities (Khalid et al., 2023; Hu et al., 2026; Shanab et al., 2025).
- Were published between 2020 and 2026.

Studies focusing exclusively on pediatric populations were not represented in the dataset. Conference abstracts (Acharya et al., 2024; Meda et al., 2024) were included for contextual analysis but interpreted cautiously due to limited reporting detail.

2.3 Study Characteristics and Evidence Base

The final dataset included:

- Large-scale meta-analyses and systematic reviews (Li et al., 2020; Yang et al., 2026; Sakima et al., 2025; Raquib et al., 2025; Ali et al., 2024; Lv et al., 2021).
- Randomized controlled trials evaluating mHealth and telemedicine interventions (Lakshminarayan et al., 2026; Prendergast et al., 2025; Buis et al., 2024; Yatabe et al., 2021; Nishizaki et al., 2023).
- Scoping and implementation reviews (Djibrilla et al., 2026; Khalid et al., 2023; Rosa et al., 2024).
- Usability and feasibility studies in low-income populations (Poblete et al., 2023).
- Reviews of wearable technologies for blood pressure monitoring (Sinou et al., 2024).
- Analyses of home blood pressure monitoring reporting patterns in telemedicine trials (Acharya et al., 2024).

To enhance transparency, the characteristics of included studies are summarized in Table 1.

Table 1. Characteristics of Included Studies

Author (Year)	Study Type	Population	Intervention Type	Key Outcomes
Yang et al. (2026)	Systematic review & meta-analysis (31 RCTs)	Adults with hypertension (n=9559)	Telemedicine + remote BP monitoring	Significant reductions in SBP, DBP; improved self-efficacy
Li et al. (2020)	Systematic review & meta-analysis (24 RCTs)	Adults with hypertension (n=8933)	mHealth self-management	SBP -3.78 mmHg; DBP -1.57 mmHg; improved adherence
Kassavou et al. (2022)	Systematic review & meta-analysis (15 RCTs)	Adults with hypertension (n=7415)	App-based behavioral self-monitoring	SBP -1.64 mmHg; greater effect with tailored advice
Sakima et al. (2025)	Systematic review & meta-analysis (117 studies)	Adults (n=68,677)	Digital health interventions	SBP -3.21 mmHg; reduced uncontrolled BP risk
Lakshminarayan et al. (2026)	RCT	High-risk diverse adults (n=395)	Pharmacist-led mHealth model	-5.8 mmHg at 6 months; sustained at 12 months
Prendergast et al. (2025)	RCT	Urban ED patients (n=574)	Education + mHealth empowerment	-4.9 mmHg SBP difference
Buis et al. (2024)	RCT	Black adults with uncontrolled HTN	Culturally tailored mHealth	No between-group difference; high dropout
Yatabe et al. (2021)	RCT	Adults with uncomplicated HTN	Telemonitoring + video visits	-6 mmHg difference in home SBP
Nishizaki et al. (2023)	Cluster RCT	Adults with HTN	Video-based telemedicine	Non-inferior BP control; improved satisfaction
Lv et al. (2021)	Meta-analysis (9 RCTs)	Stroke survivors (n=1583)	Telemedicine/mHealth	SBP -5.49 mmHg
Khoong et al. (2021)	Systematic review	Urban disparity populations	mHealth interventions	Limited differential effect vs controls
Shanab et al. (2025)	Review	Disparity populations	Remote BP monitoring	Equity-focused RBPM framework
Khalid et al. (2023)	Scoping review	HTN & diabetes	Telemedicine implementation	Barriers: cost, literacy, infrastructure
Rosa et al. (2024)	Scoping review	Hypertensive adults	mHealth engagement	Engagement linked to BP control
Poblete et al. (2023)	Usability study	Low-income adults (n=179)	Digital BP self-monitoring	Low sustained compliance
Sinou et al. (2024)	Systematic review	Adults	Wearable BP devices	Continuous monitoring; telehealth linkage

Djibrilla et al. (2026)	Scoping review protocol	African women	Digital health	Protocol; mapping equity and gender barriers
Acharya et al. (2024)	Trial pattern analysis	US TM-HTN trials	SMBP reporting	Heterogeneity in SMBP reporting
Meda et al. (2024)	Systematic review (abstract)	Adults	Remote BP monitoring	Improved QoL; cost-effectiveness

(All data derived from the respective cited publications.)

2.4 Data Synthesis Strategy

Given heterogeneity across intervention modalities, follow-up duration, and outcome measures, a narrative synthesis approach was adopted rather than pooled statistical aggregation (Raquib et al., 2025; Sakima et al., 2025). Clinical effect sizes were reported as described in original meta-analyses and RCTs (Li et al., 2020; Lakshminarayan et al., 2026; Lv et al., 2021).

Evidence was categorized into four analytical domains:

- Clinical effectiveness
- Technological innovation
- Social and structural barriers
- Patient engagement and quality-of-life implications

This framework aligns with multilevel communication and implementation perspectives described in recent telemedicine literature (Hu et al., 2026; Khalid et al., 2023).

3. Results

3.1 Clinical Effectiveness of Telemedicine Interventions in Hypertension Management

3.1.1 Evidence from Systematic Reviews and Meta-Analyses

Multiple large-scale systematic reviews and meta-analyses consistently report that telemedicine and digital health interventions are associated with statistically significant reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared with usual care (Li et al., 2020; Yang et al., 2026; Sakima et al., 2025; Lv et al., 2021; Raquib et al., 2025).

In a systematic review and meta-analysis including 31 randomized controlled trials ($n = 9,559$), telemedicine interventions were associated with significant reductions in both SBP and DBP, alongside improvements in hypertension self-management efficacy (Yang et al., 2026). Similarly, a meta-analysis of 24 randomized controlled trials ($n = 8,933$) demonstrated that mobile health (mHealth) self-management interventions reduced SBP by 3.78 mmHg and DBP by 1.57 mmHg compared with control groups (Li et al., 2020).

App-based behavioral self-monitoring interventions were also associated with statistically significant SBP reductions, particularly when tailored feedback and professional support were incorporated (Kassavou et al., 2022). In this analysis of 15 randomized controlled trials ($n = 7,415$), greater BP reductions were observed in interventions integrating personalized advice compared with passive monitoring alone (Kassavou et al., 2022).

A large meta-analysis including 117 studies and 68,677 participants reported an overall mean SBP reduction of 3.21 mmHg associated with digital health interventions and a decreased risk of uncontrolled blood pressure across follow-up periods (Sakima et al., 2025). Telemedicine and mHealth interventions were similarly effective among stroke survivors, with pooled reductions in SBP of 5.49 mmHg in a meta-analysis of nine randomized trials (Lv et al., 2021).

Collectively, these findings indicate that telemedicine interventions consistently produce modest but clinically meaningful reductions in systolic blood pressure across diverse populations and delivery formats (Li et al., 2020; Sakima et al., 2025; Yang et al., 2026).

Table 2. Quantitative Summary of Blood Pressure Outcomes

Study	Study Type	Population	SBP Reduction	DBP Reduction	Additional Outcomes
Li et al. (2020)	Meta-analysis (24 RCTs)	Adults with hypertension	-3.78 mmHg	-1.57 mmHg	Improved self-management
Kassavou et al. (2022)	Meta-analysis (15 RCTs)	Adults with hypertension	-1.64 mmHg	Not specified	Stronger effects with tailored advice
Sakima et al. (2025)	Meta-analysis (117 studies)	Adults	-3.21 mmHg	Reported reduction	Reduced uncontrolled BP risk
Yang et al. (2026)	Meta-analysis (31 RCTs)	Adults with hypertension	Significant reduction	Significant reduction	Improved self-efficacy
Lv et al. (2021)	Meta-analysis (9 RCTs)	Stroke survivors	-5.49 mmHg	Reported reduction	Post-stroke BP control

(All values reported as described in original publications.)

3.1.2 Evidence from Randomized Controlled Trials

Randomized controlled trials further support the effectiveness of telemedicine interventions, though effect sizes vary according to intervention intensity and patient population (Lakshminarayan et al., 2026; Prendergast et al., 2025; Yatabe et al., 2021).

In a pharmacist-led mHealth intervention trial involving 395 high-risk adults, the intervention group achieved a 5.8 mmHg reduction in systolic blood pressure at six months, which was sustained at 12 months (Lakshminarayan et al., 2026). A randomized clinical trial conducted in an emergency department population demonstrated a 4.9 mmHg greater reduction in SBP among patients receiving an education plus mHealth empowerment intervention compared with usual care (Prendergast et al., 2025).

Home blood pressure telemonitoring combined with video consultations produced a 6 mmHg difference in home systolic blood pressure compared with standard care in a randomized trial of patients with uncomplicated hypertension (Yatabe et al., 2021). In a cluster randomized trial evaluating optimal intervals for in-person visits during video-based telemedicine management, blood pressure control was non-inferior to usual care, with improved patient satisfaction reported in the telemedicine arm (Nishizaki et al., 2023).

However, not all telemedicine interventions demonstrated superiority. In a randomized controlled trial involving Black individuals with uncontrolled hypertension, a culturally tailored mHealth intervention did not produce statistically significant differences in blood pressure compared with the control group, and attrition rates were substantial (Buis et al., 2024). These findings underscore the importance of sustained engagement and contextual adaptation in telemedicine effectiveness (Buis et al., 2024; Rosa et al., 2024).

3.1.3 Heterogeneity of Effects and Reporting

Substantial heterogeneity across studies was observed in terms of intervention design, duration, monitoring frequency, and reporting standards (Acharya et al., 2024; Sakima et al., 2025). Analysis of home blood pressure monitoring practices in U.S.-based telemedicine trials revealed variability in measurement protocols and reporting methods, potentially influencing effect size comparability (Acharya et al., 2024).

Furthermore, differences in follow-up duration, behavioral components, and integration with clinical teams contributed to variability in observed outcomes across meta-analyses (Kassavou et al., 2022; Sakima et al., 2025). These methodological differences complicate direct comparison but consistently support a directionally favorable effect of telemedicine on systolic blood pressure control (Li et al., 2020; Yang et al., 2026).

3.1.4 Quality of Life and Cost-Effectiveness Signals

Although clinical blood pressure reduction remains the primary outcome in most studies, several publications indicate potential improvements in quality-of-life measures and cost-effectiveness associated with remote blood pressure monitoring (Meda et al., 2024; Raquib et al., 2025). However, detailed reporting of validated quality-of-life instruments is limited in several abstracts and secondary analyses (Meda et al., 2024).

Summary of Clinical Effectiveness

Across systematic reviews, meta-analyses, and randomized controlled trials, telemedicine interventions for hypertension management are consistently associated with modest but clinically meaningful reductions in systolic blood pressure, with stronger effects observed in interventions incorporating structured professional support and personalized feedback (Kassavou et al., 2022; Lakshminarayan et al., 2026). Nevertheless, heterogeneity in implementation, engagement challenges, and contextual disparities moderate overall effectiveness (Buis et al., 2024; Acharya et al., 2024).

3.2 Technological Innovations in Telemedicine for Hypertension Management

Telemedicine in hypertension management encompasses a heterogeneous spectrum of digital interventions, including mobile health applications, remote blood pressure monitoring (RBPM), video-based teleconsultations, wearable devices, and integrated pharmacist-led care models (Sakima et al., 2025; Ali et al., 2024). Across studies included in this review, interventions differed in technological sophistication, degree of clinician involvement, data transmission models, and integration with healthcare systems (Yang et al., 2026; Khalid et al., 2023).

3.2.1 Mobile Health (mHealth) Applications

Mobile health applications represent one of the most widely studied modalities in digital hypertension management (Li et al., 2020; Kassavou et al., 2022). These interventions typically incorporate self-monitoring tools, medication reminders, educational content, behavioral prompts, and feedback mechanisms (Li et al., 2020).

Meta-analytic evidence indicates that mHealth-based self-management strategies are associated with modest but statistically significant reductions in systolic blood pressure, particularly when interventions include tailored feedback or professional input (Kassavou et al., 2022). Personalized behavioral advice and interactive components appear to enhance intervention effectiveness compared with passive monitoring alone (Kassavou et al., 2022).

Pharmacist-led mHealth models integrating structured follow-up and medication management have demonstrated sustained blood pressure reductions over 12 months, suggesting that hybrid digital-clinical models may produce stronger outcomes than standalone applications (Lakshminarayan et al., 2026). Similarly, emergency department-based education combined with mobile empowerment tools resulted in clinically meaningful SBP reductions, highlighting the role of structured onboarding in technology adoption (Prendergast et al., 2025).

However, engagement variability and attrition remain significant challenges in app-based interventions, particularly in populations experiencing structural inequities (Buis et al., 2024; Rosa et al., 2024).

3.2.2 Remote Blood Pressure Monitoring (RBPM)

Remote blood pressure monitoring, often integrated with cloud-based data transmission and clinician dashboards, constitutes a core component of telemedicine-based hypertension care (Yang et al., 2026; Shanab et al., 2025). RBPM enables frequent home-based measurements, reducing reliance on in-clinic visits and facilitating earlier therapeutic adjustments (Sakima et al., 2025).

Randomized trials combining home BP monitoring with video consultations demonstrated significant differences in home systolic blood pressure compared with usual care, suggesting that telemonitoring enhances treatment responsiveness (Yatabe et al., 2021). Additionally, pharmacist-led remote management models incorporating transmitted BP readings were associated with sustained reductions in SBP over one year (Lakshminarayan et al., 2026).

However, variability in measurement protocols and reporting standards across telemedicine trials complicates direct comparison of outcomes (Acharya et al., 2024). Differences in device calibration, monitoring frequency, and adherence reporting may influence effect size heterogeneity (Acharya et al., 2024; Sakima et al., 2025).

Equity-oriented analyses emphasize that RBPM may reduce structural barriers related to transportation and clinic access but requires reliable device access and digital literacy to achieve equitable benefit (Shanab et al., 2025; Khoong et al., 2021).

3.2.3 Video-Based Teleconsultation and Hybrid Care Models

Video-based telemedicine interventions aim to replace or supplement in-person visits while maintaining clinician oversight (Nishizaki et al., 2023; Yatabe et al., 2021). In a cluster randomized trial assessing optimal intervals for in-person visits during video-based hypertension management, telemedicine demonstrated non-inferior blood pressure control compared with standard care and improved patient satisfaction (Nishizaki et al., 2023).

Hybrid models combining teleconsultation with remote monitoring and medication management appear to produce stronger outcomes than isolated digital components (Lakshminarayan et al., 2026; Sakima et al., 2025). Implementation analyses suggest that structured integration into primary care workflows enhances sustainability and clinician acceptance (Khalid et al., 2023).

3.2.4 Wearable and Continuous Monitoring Technologies

Emerging wearable blood pressure monitoring technologies enable continuous or semi-continuous measurement, expanding beyond traditional cuff-based home monitoring (Sinou et al., 2024). Systematic evaluation of wearable BP devices indicates potential for integration with telehealth platforms and artificial intelligence-driven analytics, though validation protocols and standardization remain necessary (Sinou et al., 2024).

The integration of wearable devices with telemedicine infrastructures may enhance early detection of BP variability and improve longitudinal risk stratification, but evidence regarding long-term clinical superiority remains limited (Sinou et al., 2024; Sakima et al., 2025).

3.2.5 Technology–Engagement Interface

Technological effectiveness is closely linked to communication strategies and engagement mechanisms (Hu et al., 2026; Rosa et al., 2024). A multilevel communication framework highlights micro-level (patient–provider), meso-level (team-based), and macro-level (system-wide) communication determinants that influence telemedicine adoption and sustainability (Hu et al., 2026).

Scoping analyses suggest that patient activation and digital engagement mediate the relationship between technological intervention and clinical outcomes, emphasizing that technology alone is insufficient without sustained behavioral integration (Rosa et al., 2024; Khalid et al., 2023).

Table 3. Typology of Telemedicine Technologies in Hypertension Management

Technology Type	Core Components	Reported Clinical Impact	Key Implementation Considerations	Representative Studies
mHealth Apps	Self-monitoring, reminders, feedback	SBP reduction (−1.64 to −3.78 mmHg)	Engagement variability; attrition risk	Li et al. (2020); Kassavou et al. (2022)
Pharmacist-Led mHealth	Remote monitoring + medication management	Sustained −5.8 mmHg SBP	Requires integrated care team	Lakshminarayan et al. (2026)
ED-Based mHealth Empowerment	Education + mobile follow-up	−4.9 mmHg SBP	Structured onboarding important	Prendergast et al. (2025)
Remote BP Monitoring (RBPM)	Home BP transmission to clinicians	Improved BP control	Device access; reporting heterogeneity	Yang et al. (2026); Acharya et al. (2024)
Video Teleconsultation	Virtual visits replacing in-person care	Non-inferior BP control	Workflow integration required	Nishizaki et al. (2023)
Wearable Devices	Continuous BP sensing + telehealth linkage	Potential longitudinal monitoring	Validation and standardization needed	Sinou et al. (2024)

(All findings derived from cited publications.)

Summary of Technological Innovations

Telemedicine interventions in hypertension management range from simple app-based reminders to integrated hybrid care models combining remote monitoring, structured professional oversight, and teleconsultation (Sakima et al., 2025; Lakshminarayan et al., 2026). Evidence suggests that interventions incorporating clinician engagement and structured feedback demonstrate stronger and more sustained blood pressure reductions than passive digital tools alone (Kassavou et al., 2022; Lakshminarayan et al., 2026). However, technological heterogeneity, reporting variability, and engagement challenges limit direct comparability and universal scalability (Acharya et al., 2024; Khalid et al., 2023).

3.3 Social and Structural Barriers to Telemedicine Implementation

Despite consistent evidence of clinical benefit, telemedicine interventions in hypertension management are constrained by social, structural, and implementation barriers that shape adoption, engagement, and sustained effectiveness (Khalid et al., 2023; Shanab et al., 2025). Across included studies, barriers clustered around (1) digital access and literacy, (2) affordability and reimbursement, (3) sociocultural and linguistic fit, and (4) implementation capacity at organizational and system levels (Khoong et al., 2021; Poblete et al., 2023; Hu et al., 2026).

3.3.1 Digital Divide and Differential Reach

Evidence indicates that the benefits of telemedicine may not generalize uniformly across populations experiencing digital health disparities (Khoong et al., 2021; Shanab et al., 2025). In a systematic review focusing on urban populations with digital barriers (e.g., older age, limited education, and racial/ethnic minority status), mHealth interventions demonstrated a significant systolic BP reduction at 6 months in the intervention group; however, meta-analytic comparisons did not show a statistically significant difference in SBP change between intervention and control groups (Khoong et al., 2021). This pattern suggests that background care improvements, measurement effects, or co-interventions may attenuate detectable between-group differences in disparity populations (Khoong et al., 2021).

Equity-oriented analyses emphasize that remote BP monitoring programs can be adapted to reduce digital exclusion by using cellular-enabled BP devices that do not require broadband internet access or smartphones for data transmission (Shanab et al., 2025). Such approaches are positioned as structural levers to expand reach in underserved communities, particularly when paired with standardized clinical algorithms and multidisciplinary teams (Shanab et al., 2025).

3.3.2 Financial Sustainability and Reimbursement Constraints

Financial feasibility is a recurring barrier, particularly for low-income populations and safety-net settings (Poblete et al., 2023; Shanab et al., 2025). In a usability study deploying connected BP monitors among low-income patients, only a minority met the measurement frequency thresholds needed for reimbursement of device costs, raising concerns regarding sustainability under reimbursement-driven program models (Poblete et al., 2023). Engagement decreased substantially over time, highlighting the interaction between economic feasibility and longitudinal adherence (Poblete et al., 2023).

At a system level, equity-focused reviews emphasize that prevailing payment structures often fail to reimburse the digital components of remote monitoring programs or support the non-physician workforce necessary for multidisciplinary hypertension management, including nurses, pharmacists, and community health workers (Shanab et al., 2025). Implementation analyses similarly identify cost as a dominant barrier across telemedicine programs, particularly when interventions are not embedded into existing infrastructure or supported through stable financing models (Khalid et al., 2023).

3.3.3 Sociocultural, Linguistic, and Gender-Responsive Barriers

Telemedicine implementation is sensitive to sociocultural context, language needs, and gendered barriers in access to care (Khalid et al., 2023; Djibrilla et al., 2026). A scoping review protocol focusing on African women highlights disproportionate hypertension prevalence and limited control rates in sub-Saharan Africa, while noting that gender-specific needs and barriers to digital care remain insufficiently researched (Djibrilla et al., 2026). The protocol emphasizes mapping not only effectiveness but also acceptability, trust, and socioeconomic factors shaping intervention feasibility in diverse African contexts (Djibrilla et al., 2026).

Communication-focused evidence indicates that cultural and linguistic sensitivity at the team level—including interpreters and adapted communication practices—supports patient engagement and reduces attrition in telemedicine encounters (Hu et al., 2026). Implementation studies also identify lack of consideration for language and cultural needs as a frequent barrier affecting intervention acceptability and reach (Khalid et al., 2023).

3.3.4 Engagement, Attrition, and Real-World Participation

Engagement is a primary mediator of telemedicine impact and a key barrier to effectiveness in high-inequity populations (Buis et al., 2024; Rosa et al., 2024). In a randomized trial among Black individuals with uncontrolled hypertension, both intervention and control arms showed significant improvements in BP over 12 months, but no between-group differences were detected, and dropout rates approached 60% (Buis et al., 2024). These findings suggest that proactive outreach and measurement support may drive improvement even in control conditions, while sustained engagement remains a major implementation challenge (Buis et al., 2024).

Similarly, low-income deployment of connected BP monitors demonstrated declining use over time and limited compliance with recommended measurement patterns, underscoring the challenge of sustaining participation beyond early adoption phases (Poblete et al., 2023). Scoping evidence links patient engagement to improved BP outcomes and adherence, positioning engagement as both a target outcome and a mechanism of effect (Rosa et al., 2024).

3.3.5 Implementation Determinants Across Levels of the Health System

A scoping review guided by the Consolidated Framework for Implementation Research (CFIR) identified multi-level determinants shaping telemedicine implementation, with frequent barriers related to cost, patient needs and resources, and individual patient attributes such as digital literacy and competing priorities (Khalid et al., 2023). Key facilitators included user-friendly design, tailored information, embedding within existing infrastructure, and supportive implementation climates (Khalid et al., 2023).

Communication-focused evidence complements this by identifying micro-level interpersonal strategies, meso-level team strategies, and macro-level system strategies—such as ease of use and data privacy protections—as central to building trust and sustaining telemedicine engagement (Hu et al., 2026). Concerns about data privacy and security are described as a system-level factor that can inhibit adoption, particularly when patients lack clear information about how their health data are protected (Hu et al., 2026).

Table 4. Social Barriers and Equity Determinants in Hypertension Telemedicine

Barrier Domain	Manifestation	Populations Most Affected	Implications for Outcomes	Supporting Evidence
Digital access & literacy	Limited ability to use apps/tech; need for training	Older adults, limited education, minoritized groups	Reduced measurable benefit; variable adoption	Khoong et al. (2021); Khalid et al. (2023)
Connectivity requirements	Reliance on smartphones/broadband	Underserved communities	Exclusion from RBPM unless adapted	Shanab et al. (2025)
Financial sustainability	Low compliance with reimbursement thresholds	Low-income populations	Program sustainability risk; declining use	Poblete et al. (2023); Shanab et al. (2025)
Workforce & payment model gaps	Lack of reimbursement for digital components or diverse teams	Safety-net settings; disparity populations	Limits scalability; constrains multidisciplinary care	Shanab et al. (2025); Khalid et al. (2023)
Sociocultural & language barriers	Lack of linguistic/cultural tailoring	Multilingual and multicultural patients	Lower trust; reduced engagement	Hu et al. (2026); Khalid et al. (2023)
Gender-responsive gaps	Understudied needs of African women	African women, rural settings	Evidence gaps; unknown acceptability barriers	Djibrilla et al. (2026)
Engagement & attrition	High dropout; declining usage over time	Low-income and high-inequity cohorts	Diluted effectiveness; implementation failure risk	Buis et al. (2024); Poblete et al. (2023)
Data privacy concerns	Hesitancy due to confidentiality worries	Broad; heightened in distrust contexts	Lower uptake and retention	Hu et al. (2026)

(All barrier characterizations derived exclusively from the cited publications.)

Summary of Social and Structural Barriers

Across the included evidence base, telemedicine for hypertension is shaped by social determinants and implementation conditions that moderate its effectiveness (Khalid et al., 2023; Shanab et al., 2025). Digital disparities, reimbursement and sustainability constraints, sociocultural and linguistic fit, and high attrition in inequity-impacted populations emerge as recurring barriers that can limit clinical benefit despite promising efficacy signals (Khoong et al., 2021; Poblete et al., 2023; Buis et al., 2024). Equity-oriented models emphasize adaptation strategies such as cellular-enabled monitoring devices, multidisciplinary teams, and integration of services addressing social determinants of health (Shanab et al., 2025).

3.4 Impacts on Patient Engagement and Quality of Life

While blood pressure reduction remains the dominant primary outcome across telemedicine studies, patient engagement and behavioral activation emerge as central mediators of intervention effectiveness (Rosa et al., 2024; Hu et al., 2026). Several publications conceptualize engagement not merely as an ancillary outcome but as a mechanism linking technological intervention to sustained clinical benefit (Rosa et al., 2024; Khalid et al., 2023).

3.4.1 Patient Engagement as a Mechanism of Effect

A scoping review exploring hypertension patient engagement in mHealth interventions identified consistent associations between higher levels of digital engagement and improved blood pressure control and adherence behaviors (Rosa et al., 2024). Engagement dimensions included frequency of app use, self-monitoring consistency, responsiveness to reminders, and interaction with healthcare professionals (Rosa et al., 2024).

Communication strategies further shape engagement across multiple levels. A systematic review of telemedicine communication approaches identified micro-level strategies (e.g., empathetic clinician–patient interaction), meso-level strategies (e.g., team-based communication coordination), and macro-level strategies (e.g., system usability and privacy safeguards) as determinants of sustained participation (Hu et al., 2026). These multilevel determinants influence patient activation, trust, and long-term adherence to telemonitoring protocols (Hu et al., 2026).

Implementation-focused analyses similarly emphasize that patient-centered design, tailored information, and user-friendly platforms act as facilitators of engagement, whereas complexity, poor interface design, and misalignment with patient needs reduce uptake (Khalid et al., 2023).

3.4.2 Engagement Variability and Attrition

Despite documented benefits, sustained engagement remains inconsistent across populations and intervention models (Buis et al., 2024; Poblete et al., 2023). In a randomized trial among Black individuals with uncontrolled hypertension, substantial attrition was observed over 12 months, and no statistically significant between-group differences in blood pressure were detected despite improvements within both arms (Buis et al., 2024). These findings suggest that engagement intensity and retention may critically influence detectable intervention effects (Buis et al., 2024).

Similarly, in a low-income population deploying digitally connected BP monitors, usage declined markedly over time, and only a small proportion of participants maintained measurement frequency sufficient to meet reimbursement thresholds (Poblete et al., 2023). The decline in adherence highlights the interaction between socioeconomic constraints and behavioral sustainability in digital health programs (Poblete et al., 2023).

These findings reinforce the interpretation that telemedicine effectiveness is contingent not solely on technological availability but on longitudinal behavioral integration (Rosa et al., 2024; Khalid et al., 2023).

3.4.3 Self-Management Efficacy and Behavioral Outcomes

Several meta-analyses report improvements in self-management efficacy and behavioral outcomes associated with telemedicine interventions (Yang et al., 2026; Li et al., 2020). Digital self-management programs were associated with enhanced adherence behaviors and self-monitoring consistency compared with usual care (Li et al., 2020). Telemedicine interventions incorporating structured feedback were linked to improved self-efficacy in hypertension management (Yang et al., 2026).

App-based behavioral interventions demonstrated greater blood pressure reductions when tailored advice was included, further supporting the behavioral mediation hypothesis (Kassavou et al., 2022). These findings indicate that the behavioral component of telemedicine—rather than passive monitoring alone—contributes to clinical benefit (Kassavou et al., 2022; Lakshminarayan et al., 2026).

3.4.4 Quality of Life and Patient Satisfaction

Although quality of life (QoL) outcomes are less frequently reported than blood pressure endpoints, some evidence highlights potential improvements associated with remote monitoring and telemedicine integration (Meda et al., 2024; Raquib et al., 2025). However, detailed reporting of validated QoL instruments and long-term psychosocial outcomes is limited in several publications, particularly in abstract-only reports (Meda et al., 2024).

Video-based telemedicine interventions demonstrated improved patient satisfaction compared with standard in-person care in a cluster randomized trial, indicating that perceived convenience and acceptability may constitute important patient-centered outcomes (Nishizaki et al., 2023). Satisfaction gains may relate to reduced travel burden, increased scheduling flexibility, and perceived continuity of monitoring (Nishizaki et al., 2023; Hu et al., 2026).

Nevertheless, the heterogeneity of QoL reporting and limited standardization across studies restrict the ability to draw firm conclusions regarding long-term psychosocial benefit (Raquib et al., 2025; Sakima et al., 2025).

3.4.5 Integration of Engagement and Clinical Outcomes

Evidence across the dataset suggests a conceptual pathway in which technological intervention influences engagement, which in turn mediates blood pressure control (Rosa et al., 2024; Hu et al., 2026). Interventions combining digital monitoring with structured professional oversight demonstrate stronger and more sustained blood pressure reductions than passive digital platforms alone (Lakshminarayan et al., 2026; Kassavou et al., 2022).

Conversely, high attrition and insufficient behavioral integration may attenuate detectable intervention effects, even in well-designed trials (Buis et al., 2024; Poblete et al., 2023). Thus, engagement emerges as both an outcome and a determinant of telemedicine effectiveness (Rosa et al., 2024; Khalid et al., 2023).

Overall Synthesis of Results

Across systematic reviews, randomized controlled trials, scoping analyses, and implementation studies, telemedicine interventions for hypertension demonstrate consistent though modest reductions in systolic blood pressure, particularly when interventions incorporate personalized feedback and structured professional involvement (Li et al., 2020; Yang et al., 2026; Lakshminarayan et al., 2026). Technological heterogeneity, reporting variability, and contextual inequities moderate effect sizes (Acharya et al., 2024; Khalid et al., 2023).

Social determinants—including digital access, financial sustainability, sociocultural fit, and engagement sustainability—substantially influence intervention reach and durability (Khoong et al., 2021; Poblete et al., 2023; Shanab et al., 2025). Patient engagement operates as a central mediator linking technological innovation to clinical outcomes and perceived benefit (Rosa et al., 2024; Hu et al., 2026).

4. Discussion

4.1 Principal Findings

This structured review synthesizes evidence from systematic reviews, meta-analyses, randomized controlled trials, and implementation analyses published between 2020 and 2026, demonstrating that telemedicine interventions are consistently associated with modest but statistically significant reductions in systolic blood pressure across diverse adult populations (Li et al., 2020; Yang et al., 2026; Sakima et al., 2025; Lv et al., 2021). The magnitude of SBP reduction across meta-analyses generally ranges from approximately 1.6 to 5.5 mmHg, with larger reductions observed in interventions incorporating structured professional support and higher intervention intensity (Kassavou et al., 2022; Lakshminarayan et al., 2026; Lv et al., 2021).

Hybrid models combining remote blood pressure monitoring with pharmacist or clinician oversight demonstrate more sustained and clinically meaningful improvements than passive or minimally interactive digital tools (Lakshminarayan et al., 2026; Sakima et al., 2025). This pattern supports the interpretation that telemedicine effectiveness is mediated not solely by technological access but by structured clinical integration and behavioral reinforcement (Kassavou et al., 2022; Khalid et al., 2023).

However, effect sizes vary substantially across populations and implementation contexts, and not all randomized trials demonstrate superiority over usual care (Buis et al., 2024; Khoong et al., 2021). These inconsistencies underscore the importance of engagement, contextual adaptation, and implementation quality as determinants of measurable benefit (Rosa et al., 2024; Khalid et al., 2023).

4.2 Clinical Significance and Heterogeneity

Although the magnitude of SBP reduction is modest, the reproducibility of findings across independent meta-analyses reinforces confidence in the overall effectiveness of telemedicine interventions (Li et al., 2020; Sakima et al., 2025; Yang et al., 2026).

Heterogeneity arises from variation in intervention components, follow-up duration, measurement protocols, and reporting standards (Acharya et al., 2024; Sakima et al., 2025). Differences in home BP monitoring frequency, device validation, and reporting approaches complicate direct comparison across trials (Acharya et al., 2024). Additionally, intervention intensity and personalization appear to influence outcomes, with tailored feedback and clinician involvement producing stronger effects than automated or passive monitoring alone (Kassavou et al., 2022; Lakshminarayan et al., 2026).

These findings suggest that telemedicine should be conceptualized not as a singular intervention category but as a continuum of models with variable clinical potency depending on implementation design (Sakima et al., 2025; Khalid et al., 2023).

4.3 Equity, Access, and Structural Determinants

A central insight emerging from this synthesis is that telemedicine effectiveness is strongly shaped by structural and social determinants (Khoong et al., 2021; Shanab et al., 2025). Digital literacy, device access, broadband connectivity, language adaptation, and reimbursement models influence both adoption and sustained engagement (Khalid et al., 2023; Hu et al., 2026).

Evidence from populations experiencing digital barriers indicates that intervention groups may demonstrate improvements over time without statistically significant differences compared with control groups, potentially reflecting measurement effects or parallel improvements in standard care (Khoong et al., 2021). High attrition rates observed in trials among historically marginalized populations further highlight the fragility of engagement in real-world conditions (Buis et al., 2024; Poblete et al., 2023).

Equity-oriented models propose that cellular-enabled devices, multidisciplinary care teams, and integration of social determinants screening may reduce exclusion and enhance reach (Shanab et al., 2025). However, financial sustainability remains a concern when reimbursement structures fail to support digital components or non-physician workforce contributions (Poblete et al., 2023; Shanab et al., 2025).

Gender-responsive and region-specific research gaps persist, particularly in African contexts where hypertension burden is high and digital health research remains underdeveloped (Djibrilla et al., 2026). Thus, telemedicine expansion without deliberate equity adaptation risks reinforcing existing disparities rather than mitigating them (Khoong et al., 2021; Shanab et al., 2025).

4.4 Patient Engagement as a Central Mediator

Engagement emerges as both a mediator and an outcome of telemedicine interventions (Rosa et al., 2024; Hu et al., 2026). Evidence suggests that higher levels of digital interaction, consistent self-monitoring, and structured communication correlate with improved blood pressure control (Rosa et al., 2024; Kassavou et al., 2022).

Communication strategies operating at micro-, meso-, and macro-levels influence trust, usability, and retention (Hu et al., 2026). Implementation analyses further demonstrate that user-friendly design, tailored content, and alignment with patient needs facilitate sustained adoption, whereas complexity and lack of contextual adaptation impede engagement (Khalid et al., 2023).

The divergence between trials showing strong BP reductions and those demonstrating null between-group effects may partially reflect differences in engagement intensity rather than intrinsic inefficacy of telemedicine (Lakshminarayan et al., 2026; Buis et al., 2024). These findings support a behavioral mediation model in which technological infrastructure requires continuous relational and contextual reinforcement to maintain clinical benefit (Rosa et al., 2024; Khalid et al., 2023).

4.5 Quality of Life and Patient-Centered Outcomes

Compared with blood pressure endpoints, quality-of-life outcomes are less consistently reported and less standardized across studies (Meda et al., 2024; Raquib et al., 2025). Available signals suggest potential improvements in satisfaction and convenience, particularly in video-based telemedicine models demonstrating non-inferior BP control and higher patient satisfaction compared with in-person care (Nishizaki et al., 2023).

However, limited reporting of validated QoL instruments restricts firm conclusions regarding long-term psychosocial benefit (Meda et al., 2024; Sakima et al., 2025). Future research should prioritize standardized assessment of patient-reported outcomes to complement clinical metrics and better capture the lived experience of telemedicine-based care (Raquib et al., 2025; Rosa et al., 2024).

4.6 Strengths and Limitations of the Evidence Base

The evidence synthesized in this review includes large meta-analyses with substantial sample sizes and multiple randomized controlled trials, strengthening confidence in the directionality of clinical effects (Li et al., 2020; Sakima et al., 2025; Yang et al., 2026). The inclusion of implementation and communication-focused studies allows integration of structural and behavioral perspectives alongside clinical outcomes (Khalid et al., 2023; Hu et al., 2026).

Nevertheless, limitations are evident. Considerable heterogeneity in intervention components and outcome reporting complicates direct comparison (Acharya et al., 2024; Sakima et al., 2025). Attrition and engagement decline in real-world populations may attenuate sustained benefit (Buis et al., 2024; Poblete et al., 2023). Furthermore, several analyses rely on short- to medium-term follow-up, limiting inference regarding long-term cardiovascular outcomes (Li et al., 2020; Sakima et al., 2025).

Additionally, certain sources included in this synthesis are conference abstracts with limited methodological detail, necessitating cautious interpretation (Acharya et al., 2024; Meda et al., 2024).

4.7 Implications for Practice and Future Research

Across the evidence base telemedicine should be implemented as an integrated, team-based model incorporating structured monitoring, personalized feedback, and equity-adapted delivery mechanisms rather than as a standalone technological add-on (Lakshminarayan et al., 2026; Shanab et al., 2025). Implementation strategies should prioritize digital literacy support, culturally and linguistically tailored communication, and financing models that sustain multidisciplinary participation (Khalid et al., 2023; Hu et al., 2026).

Future research should:

- Standardize reporting of home BP monitoring protocols to improve comparability (Acharya et al., 2024).
- Incorporate validated quality-of-life instruments and long-term patient-reported outcomes (Raquib et al., 2025; Rosa et al., 2024).
- Conduct gender-responsive and region-specific studies in underrepresented populations (Djibrilla et al., 2026).
- Examine strategies to reduce attrition and sustain engagement over extended follow-up (Buis et al., 2024; Poblete et al., 2023).

Telemedicine in hypertension management appears most effective when technological innovation, clinical integration, and equity-oriented implementation are addressed simultaneously (Shanab et al., 2025; Khalid et al., 2023).

5. Conclusions

Telemedicine and digital health interventions in hypertension management are consistently associated with modest but statistically significant reductions in systolic blood pressure across diverse adult populations, as demonstrated in multiple systematic reviews, meta-analyses, and randomized controlled trials (Li et al., 2020; Yang et al., 2026; Sakima et al., 2025; Lv et al., 2021). Interventions integrating structured professional oversight, personalized feedback, and remote blood pressure monitoring appear to yield stronger and more sustained clinical effects than passive or minimally interactive digital tools (Kassavou et al., 2022; Lakshminarayan et al., 2026).

However, telemedicine effectiveness is not uniform and is strongly shaped by engagement dynamics, implementation design, and structural determinants, including digital literacy, socioeconomic constraints, reimbursement structures, and sociocultural adaptation (Khoong et al., 2021; Khalid et al., 2023; Shanab et al., 2025). High attrition and engagement decline in certain populations, particularly among historically marginalized groups, highlight the need for equity-oriented implementation strategies and sustained behavioral support (Buis et al., 2024; Poblete et al., 2023).

Patient engagement functions as a central mediator linking technological innovation to clinical outcomes, with communication strategies and system-level facilitators influencing adoption, retention, and satisfaction (Rosa et al., 2024; Hu et al., 2026). Although preliminary evidence suggests potential improvements in patient satisfaction and convenience, standardized assessment of long-term quality-of-life outcomes remains limited (Meda et al., 2024; Raquib et al., 2025).

Overall, telemedicine represents a promising but context-dependent paradigm in hypertension care. Its sustainable and equitable impact depends on integration within multidisciplinary care models, adaptation to social determinants of health, standardized monitoring protocols, and prioritization of patient-centered

engagement mechanisms (Shanab et al., 2025; Khalid et al., 2023; Acharya et al., 2024). Future research should emphasize long-term outcomes, standardized reporting, and equity-focused implementation frameworks to ensure that digital innovation translates into durable and inclusive cardiovascular risk reduction (Djibrilla et al., 2026; Rosa et al., 2024).

Acknowledgments: The author(s) did not receive any specific funding for the preparation of this manuscript. No external financial support was provided for this work.

Conflict of Interest Statement: The author(s) declare that there are no conflicts of interest related to this work.

REFERENCES

1. Acharya, S., Neupane, G., Seals, A., et al. (2024). Patterns of home blood pressure monitor use in US-based clinical trials of telemedicine management of hypertension. *Journal of the American College of Cardiology*, 83(13_Supplement), 1765. [https://doi.org/10.1016/S0735-1097\(24\)03755-0](https://doi.org/10.1016/S0735-1097(24)03755-0)
2. Ali, S. H. M., Osman Mohamed, A. A., Osman, H. M. M., Abdelrahman Ibrahim, M. E., Hassan Mukhtar, M. A., Ahmed Mohamed, F. H., & Alhajri, A. H. M. (2024). The role of telemedicine in improving hypertension management outcomes: A systematic review. *Cureus*, 16(11), e74090. <https://doi.org/10.7759/cureus.74090>
3. Buis, L. R., Kim, J., Sen, A., Chen, D., Dawood, K., Kadri, R., Muladore, R., Plegue, M., Richardson, C. R., Djuric, Z., McNaughton, C., Hutton, D., Robert, L. P., Park, S. Y., & Levy, P. (2024). The effect of an mHealth self-monitoring intervention (MI-BP) on blood pressure among Black individuals with uncontrolled hypertension: Randomized controlled trial. *JMIR mHealth and uHealth*, 12, e57863. <https://doi.org/10.2196/57863>
4. Djibrilla, S., Mandeng Ma Linwa, E., Bonghaseh, T. D., & Kamdem, F. (2026). Digital health interventions for hypertension management in African women: A scoping review protocol. *Systematic Reviews*. Advance online publication. <https://doi.org/10.1186/s13643-026-03081-5>
5. Hu, Y., Ngai, C., & Jiang, R. (2026). Communication strategies to promote patient engagement in telemedicine: Systematic review. *Journal of Medical Internet Research*, 28, e85456. <https://doi.org/10.2196/85456>
6. Kassavou, A., Wang, M., Mirzaei, V., Shpendi, S., & Hasan, R. (2022). The association between smartphone app-based self-monitoring of hypertension-related behaviors and reductions in high blood pressure: Systematic review and meta-analysis. *JMIR mHealth and uHealth*, 10(7), e34767. <https://doi.org/10.2196/34767>
7. Khalid, A., Dong, Q., Chuluunbaatar, E., Haldane, V., Durrani, H., & Wei, X. (2023). Implementation science perspectives on implementing telemedicine interventions for hypertension or diabetes management: Scoping review. *Journal of Medical Internet Research*, 25, e42134. <https://doi.org/10.2196/42134>
8. Khoong, E. C., Olazo, K., Rivadeneira, N. A., Thatipelli, S., Barr-Walker, J., Fontil, V., Lyles, C. R., & Sarkar, U. (2021). Mobile health strategies for blood pressure self-management in urban populations with digital barriers: Systematic review and meta-analyses. *npj Digital Medicine*, 4(1), 114. <https://doi.org/10.1038/s41746-021-00486-5>
9. Lakshminarayan, K., Murray, T. A., Lunos, S., McCarthy, T., Everson-Rose, S. A., Overton, V., Drawz, P., Streib, C., Sakboonyarat, B., Hatch, H., Hibbard, J. H., Luepker, R., Connett, J., & Westberg, S. M. (2026). mHealth intervention to improve hypertension care in high-risk patients. *Hypertension*. Advance online publication. <https://doi.org/10.1161/HYPERTENSIONAHA.125.26148>
10. Li, R., Liang, N., Bu, F., & Hesketh, T. (2020). The effectiveness of self-management of hypertension in adults using mobile health: Systematic review and meta-analysis. *JMIR mHealth and uHealth*, 8(3), e17776. <https://doi.org/10.2196/17776>
11. Lv, M., Wu, T., Jiang, S., Chen, W., & Zhang, J. (2021). Effects of telemedicine and mHealth on systolic blood pressure management in stroke patients: Systematic review and meta-analysis of randomized controlled trials. *JMIR mHealth and uHealth*, 9(6), e24116. <https://doi.org/10.2196/24116>
12. Meda, V. S. A., Adhikari, A., Tadiogola, C., Gaddam, A. R., Vaghamsashi, Y., Gupta, U., & Panjiyar, B. K. (2024). Abstract 4138494: Remote blood pressure monitoring and intervention as a better and cost-effective method of hypertension control compared to usual care: A systematic review. *Circulation*, 150(Suppl_1). https://doi.org/10.1161/circ.150.suppl_1.4138494
13. Nishizaki, Y., Kuroki, H., Ishii, S., Ohtsu, S., Watanabe, C., Nishizawa, H., Nagao, M., Nojima, M., Watanabe, R., Sato, D., Sato, K., Kawata, Y., Wada, H., Toyoda, G., & Ohbayashi, K. (2023). Determining optimal intervals for in-person visits during video-based telemedicine among patients with hypertension: Cluster randomized controlled trial. *JMIR Cardio*, 7, e45230. <https://doi.org/10.2196/45230>
14. Poblete, J., Vawter, N., Lewis, S., Felisme, E., Mohn, P., Shea, J., Northrup, A., Liu, J., Al-Rousan, T., & Godino, J. (2023). Digitally based blood pressure self-monitoring program that promotes hypertension self-management and health education among patients with low income: Usability study. *JMIR Human Factors*, 10, e46313. <https://doi.org/10.2196/46313>

15. Prendergast, H., Kitsiou, S., Petzel Gimbar, R., Freels, S., Sanders, A., Daviglius, M., Kotini-Shah, P., Carter, B., Del Rios, M., Heinert, S., & Khosla, S. (2025). Emergency department-based education and mHealth empowerment intervention for hypertension: The TOUCHED randomized clinical trial. *JAMA Cardiology*, *10*(7), 657–665. <https://doi.org/10.1001/jamacardio.2025.0675>
16. Raquib, N., Alshibane, M. A. M., Awad Elkarim, N. H. M., Osman, A., Ahmed, Y., Elhaj, F. M. A., & Abbas, I. M. A. D. (2025). Digital health and telemedicine interventions for hypertension management in adults: A systematic review. *Cureus*, *17*(11), e97024. <https://doi.org/10.7759/cureus.97024>
17. Rosa, D., Peverelli, M., Poliani, A., Villa, G., & Manara, D. F. (2024). Exploring hypertension patient engagement using mHealth: A scoping review. *High Blood Pressure & Cardiovascular Prevention*, *31*(4), 341–357. <https://doi.org/10.1007/s40292-024-00656-y>
18. Sakima, A., Akagi, Y., Akasaki, Y., Fujii, T., Haze, T., Kawakami-Mori, F., Kitajima, K., Kobayashi, Y., Matayoshi, T., Sakaguchi, T., Yamazato, M., Abe, M., Ohya, Y., & Arima, H. (2025). Effectiveness of digital health interventions for telemedicine/telehealth for managing blood pressure in adults: A systematic review and meta-analysis. *Hypertension Research*, *48*(2), 478–491. <https://doi.org/10.1038/s41440-024-01792-7>
19. Shanab, B. M., Gaffey, A. E., Schwamm, L., Zawalich, M., Sarpong, D. F., Pérez-Escamilla, R., Dorney, J., Cooperman, C., Schafer, R., Lipkind, H. S., Lu, Y., Onuma, O. K., & Spatz, E. S. (2025). Closing the gap: Digital innovations to address hypertension disparities. *Current Cardiology Reports*, *27*(1), 23. <https://doi.org/10.1007/s11886-024-02171-x>
20. Sinou, M., Achilleos, N., Kyriakou, M., & Pattichis, C. S. (2024). Wearable blood pressure monitoring devices and their integration into telemedicine systems: A systematic review. *Journal of Clinical Medicine*, *13*(3), 836. <https://doi.org/10.3390/jcm13030836>
21. Yatabe, J., Yatabe, M., Okada, R., & Ichihara, A. (2021). Efficacy of telemedicine in hypertension care through home blood pressure monitoring and videoconferencing: Randomized controlled trial. *JMIR Cardio*, *5*(2), e27347. <https://doi.org/10.2196/27347>
22. Yang, G., Zhang, N., Zhang, Y., Sa, R., & Zhao, L. (2026). Effectiveness of telemedicine interventions on blood pressure control and self-management efficacy in hypertensive patients: A systematic review and meta-analysis. *Frontiers in Public Health*, *13*, 1693141. <https://doi.org/10.3389/fpubh.2025.1693141>